JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2022, Volume and Issue: 149(2), P. 179 - 179
Published: Dec. 15, 2022
This prospective observational study examines if circulating tumor human papillomavirus DNA can be used as an accurate measure of disease status at the time diagnosis, throughout treatment, and during monitoring in papillomavirus-associated sinonasal nasopharyngeal squamous cell carcinomas.
Language: Английский
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 26, 2025
Integration of human papillomavirus (HPV) into the host genome drives HPV-positive head and neck squamous cell carcinoma (HPV+ HNSCC). Whole-genome sequencing 51 tumors revealed intratumor heterogeneity HPV integration, with 44% breakpoints subclonal, a biased distribution integration across genome. Four physical states were identified, at least 49% progressing without integration. was associated APOBEC-induced broad genomic instability focal instability, including structural variants sites. HPV+ HNSCCs exhibited almost no smoking-induced mutational signatures. Heterozygous loss ataxia-telangiectasia mutated (ATM) observed in 67% tumors, its downregulation confirmed by single-cell RNA immunohistochemistry, suggesting ATM haploinsufficiency contributes to carcinogenesis. PI3K activation major oncogenic mutation, JAK-STAT clonal NF-kappa B those without. These findings provide valuable insights HNSCC. The Here, authors perform analysis investigate patients HNSCC, identifying
Language: Английский
Citations
2
JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2022, Volume and Issue: 148(12), P. 1120 - 1120
Published: Oct. 27, 2022
Circulating tumor tissue-modified viral (TTMV) human papillomavirus (HPV) DNA is a dynamic, clinically relevant biomarker for HPV-positive oropharyngeal squamous cell carcinoma. Reasons its wide pretreatment interpatient variability are not well understood.To characterize clinicopathologic factors associated with TTMV HPV DNA.This cross-sectional study included patients evaluated carcinoma at Dana-Farber Cancer Institute in Boston, Massachusetts, between December 2019 and January 2022 who were undergoing curative-intent treatment.Clinicopathologic characteristics including demographic variables, nodal staging, genotype, imaging findings.Pretreatment circulating from 5 genotypes (16, 18, 31, 33, 35) assessed using commercially available digital droplet polymerase chain reaction-based assay, considered as either detectable/undetectable or continuous score (fragments/mL).Among 110 patients, 96 men (87%) 104 White (95%), mean (SD) age of 62.2 (9.4) years. was detected 98 (89%), median (IQR) 315 (47-2686) fragments/mL (range, 0-60 061 fragments/mL). Most detectable genotype 16 (n = 86 [88%]), while 12 (12%) harbored other genotypes. detection most strongly clinical N stage. Although few had stage N0 disease, only 4 these 11 (36%) compared 94 99 (95%) N1 to N3 disease (proportion difference, 59%; 95% CI, 30%-87%). Among undetectable DNA, more than half (7 [58%]) disease. The prevalence increased progressively higher stage, diameter largest lymph node, maximum standardized uptake value on positron emission tomography/computed tomography. In multivariable analysis, each score. 27 surgically treated without lymphovascular invasion (12 [100%] vs 9 15 [60%]).In this study, statistically significantly OPSCC diagnosis. levels predominantly suggesting assay sensitivity diagnostic purposes may be lower among cervical lymphadenopathy. Mechanisms underlying association, the use surveillance baseline values, warrant further investigation.
Language: Английский
Citations
39
Cancer, Journal Year: 2023, Volume and Issue: 129(18), P. 2817 - 2827
Published: May 10, 2023
Development of evidence-based post-treatment surveillance guidelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is limited by comprehensive documentation patterns recurrence metastatic spread.A retrospective analysis patients diagnosed with R/M HNSCC at a National Cancer Institute-designated cancer center between 1998- 2019 was performed (n = 447). Univariate multivariate identified predictors survival.Median overall survival (mOS) improved over time (6.7 months 1998-2007 to 11.8 2008-2019, p .006). Predictors worse mOS included human papillomavirus (HPV) negativity (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.2-2.6), high neutrophil/lymphocyte (HR, 2.1 [1.4-3.0], disease-free (DFI) ≤6 1.4 [1.02-2.0]), poor performance status (Eastern Cooperative Oncology Group, ≥2; HR, 1.91.1-3.4). In this cohort, 50.6% recurrences occurred within 6 treatment completion, 72.5% 1 year, 88.6% 2 years. Metachronous distant metastases were more likely occur HPV-positive disease (odds [OR], 2.3 [1.4-4.0]), DFI >6 (OR, 2.4 [1.5-4.0]), body mass index ≥30 [1.1-4.8]). Oligometastatic treated local ablative therapy associated polymetastatic 0.36; CI, 0.24-0.55).These data regarding metastasis support the clinical utility early detection recurrence. Patterns population can be used inform individualized programs as well risk-stratify eligible for trials.After (HNC), are risk prior sites or body. This study includes large group recurrent HNC examines factors outcomes patterns. Patients (HPV)-positive have good outcomes, but if they recur, may regions later than HPV-negative patients. These argue personalized follow-up schedules HNC, perhaps incorporating imaging studies novel blood tests.
Language: Английский
Citations
36
Periodontology 2000, Journal Year: 2023, Volume and Issue: 96(1), P. 250 - 280
Published: Dec. 10, 2023
The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per from 2005 to 2017, higher rates when detected at early stages. Based on histopathological grading dysplasia, it is estimated that severe dysplasia malignant transformation 7%-50%. Despite these numbers, does not reliably predict its clinical behavior. Thus, more accurate markers predicting progression cancer would enable better targeting lesions for closer follow-up, especially stages disease. In this context, molecular biomarkers derived genetics, proteins, and metabolites play key roles oncology. These signatures can help likelihood OSCC development and/or have potential detect disease an stage and, support treatment decision-making responsiveness. Also, identifying reliable detection be obtained non-invasively enhance management OSCC. This review will discuss emerged different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, microbiomics.
Language: Английский
Citations
29
Practical Radiation Oncology, Journal Year: 2024, Volume and Issue: 14(5), P. 398 - 425
Published: June 18, 2024
Human Papilloma Virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is a distinct disease from other head and neck tumors. This guideline provides evidence-based recommendations on the critical decisions in its curative treatment, including both definitive postoperative radiation therapy (RT) management.
Language: Английский
Citations
9
Oral Oncology, Journal Year: 2025, Volume and Issue: 161, P. 107179 - 107179
Published: Jan. 18, 2025
Language: Английский
Citations
1
European Archives of Oto-Rhino-Laryngology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 25, 2025
Language: Английский
Citations
1
Oral Oncology, Journal Year: 2022, Volume and Issue: 126, P. 105776 - 105776
Published: Feb. 17, 2022
Language: Английский
Citations
36
JAMA Oncology, Journal Year: 2023, Volume and Issue: 9(12), P. 1716 - 1716
Published: Oct. 12, 2023
Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma has an overall favorable prognosis, yet a subset of patients will experience devastating disease recurrence. Current surveillance standards for detection recurrent are imperfect. There is growing interest in improving through the use plasma-based assays able to detect circulating tumor HPV DNA.Although most DNA remain research domain, tissue-modified viral assay became commercially available United States early 2020 and been increasingly used clinical setting. With rapidly increasing incidence HPV-positive concomitant expansion biomarker capabilities this disease, it critical reexamine current posttreatment practices determine whether emerging technologies may be improve outcomes survivor population. However, caution advised; not known biomarker-based truly beneficial, as true with any intervention, capacity cause harm.Using Margaret Pepe's classic 5 phases development cancer framework, article reviews state knowledge, highlights existing knowledge gaps, suggests that should prioritized understand association between patient outcomes. Specific attention paid assay, given its use. This review serve road map future guide clinicians considering adoption practice. Enrollment into trials incorporating prioritized.
Language: Английский
Citations
17
JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2024, Volume and Issue: 150(5), P. 444 - 444
Published: April 4, 2024
Importance The utility of preoperative circulating tumor tissue-modified viral human papillomavirus DNA (TTMV-HPV DNA) levels in predicting (HPV)–associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) disease burden is unknown. Objective To determine if HPV (ctHPVDNA) associated with patients HPV+ OPSCC who have undergone transoral robotic surgery (TORS). Design, Setting, and Participants This cross-sectional study comprised underwent primary TORS between September 2021 April 2023 at one tertiary academic institution. Patients treatment-naive (p16-positive) ctHPVDNA were included, those neck mass excision before collection excluded. Main Outcomes Measures main outcome was the association increasing size lymph node involvement surgical pathology. secondary adverse pathology, which included lymphovascular invasion, perineural or extranodal extension. Results A total 70 (65 men [93%]; mean [SD] age, 61 [8] years). Baseline ranged from 0 fragments/milliliter plasma (frag/mL) to 49 452 frag/mL (median [IQR], 272 [30-811] frag/mL). Overall, 58 (83%) had positive results for ctHPVDNA, 1 (1.4%) indeterminate results, 11 (15.6%) negative results. sensitivity detectable identifying pathology-confirmed 84%. Twenty-seven (39%) pathologic (pT) staging pT0 pT1, 34 (49%) pT2 staging, 9 (13%) pT3 pT4 staging. No clinically meaningful difference undetectable cohorts found Although median appeared be higher through stages pN1 pN2 stages, effect sizes small (pT stage: η2, 0.002 [95% CI, −1.188 0.827]; pN 0.043 −0.188 2.600]). Median log(TTMV-HPV active smokers (8.79 3.55-5.76]), compared never (5.92 −0.97 1.81]) former (4.99 0.92-6.23]). Regression analysis did not show an dimension metastatic deposit DNA). After univariate analysis, no Conclusions Relevance In this study, TORS.
Language: Английский
Citations
5